Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19

BACKGROUND: The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation. METHODS: IV AAT was a...

Descripción completa

Detalles Bibliográficos
Autores principales: McElvaney, Oliver J, O'Connor, Eoin, McEvoy, Natalie L, Fraughan, Daniel D, Clarke, Jennifer, McElvaney, Oisín F, Gunaratnam, Cedric, O'Rourke, James, Curley, Gerard F, McElvaney, Noel G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678455/
https://www.ncbi.nlm.nih.gov/pubmed/33288475
http://dx.doi.org/10.1016/j.jcf.2020.11.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678455/
https://www.ncbi.nlm.nih.gov/pubmed/33288475
http://dx.doi.org/10.1016/j.jcf.2020.11.012

Ejemplares similares